Switching antiretroviral regimes for the treatment of HIV: safety implications

References

• Department of Health and Human Services (DHHS). Guidelines for the use of antiretroviral agents in HIV-1- infected adults and adolescents. Developed by the HHS panel on antiretroviral guidelines for adults and adolescents—a working group of the Office of AIDS Research Advisory Council (OARAC). [updated 2016 Jan 28; reviewed 2016 Jan 28; cited 2016 Mar 30]. Available from: http://aidsinfo.nih.gov/guidelines.
   Google Scholar
• Fisher M, Moyle GJ, Shahmanesh M, et al. A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individuals. J Acquir Immune Defic Syndr. 2009;51:562–568.
   PubMed Web of Science ®Google Scholar
• Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral- naive patients: a 3-year randomized trial. JAMA. 2004;292:191–201.
   PubMed Web of Science ®Google Scholar
• Pedrol E, Viciana P, Arranz A, et al. [Reasons for antiretroviral treatment change in HIV+ patients in Spain in 2010-2011. SWITCH AUDIT study]. Rev Esp Quimioter. 2014;27(2):93–97. Spanish.
   PubMed Web of Science ®Google Scholar
• Carr A, Workman C, Smith DE, et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy. JAMA. 2002;288:207–215.
   PubMed Web of Science ®Google Scholar
• Cohen C, Wohl D, Arribas JR, et al. Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults. AIDS. 2014;28:989–997.
   PubMed Web of Science ®Google Scholar
• Pozniak A, Markowitz M, Mills A, et al. Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial. Lancet Infect Dis. 2014;14:590–599.
   PubMed Web of Science ®Google Scholar
• Marins JRP, Jamal LF, Chen SY, et al. Dramatic improvement in survival among adult Brazilian AIDS patients. AIDS. 2003;17:1675–1682.
   PubMed Web of Science ®Google Scholar
• Mills A, Arribas JR, Andrade-Villanueva J, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. Lancet Infect Dis. 2016;16:43–52.
   PubMed Web of Science ®Google Scholar
• Hall AM, Hendry BM, Nitsch D, et al. Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kidney Dis. 2011;57:773–780.
   PubMed Web of Science ®Google Scholar
• Günthard HF, Aberg JA, Eron JJ, et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society–USA panel. JAMA. 2014;312(4):410–425. doi:10.1001/jama.2014.8722.
   PubMed Web of Science ®Google Scholar
• European AIDS Clinical Society (EACS). Guidelines for the clinical management and treatment of HIV infected adults in Europe. Version 8.0 - October 2015. [ cited March 30, 2016]. Available from: http://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html.
   Google Scholar
• Squires KE, Young B, Dejesus E, et al. Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients. AIDS. 2010;24:2019–2027.
   PubMed Web of Science ®Google Scholar
• Wohl DA, Bhatti L, Small CB, et al. Simplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trial. PLoS One. 2014;9:e96187.
   PubMed Web of Science ®Google Scholar
• Domingo P, Vidal F. Reducing atazanavir dose: one size does not fit all. Lancet HIV. 2016 Forthcoming.
   PubMed Web of Science ®Google Scholar
• Fabbiani M, Di Giambenedetto S, Quiros-Roldan E, et al. Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial. J Int AIDS Soc. 2014;17(4 Suppl 3):19808.
   PubMed Web of Science ®Google Scholar
• Stephan C. Virological efficacy and safety of antiretroviral therapy-switch to atazanavir-based regimen: a review of the literature. Expert Opin Pharmacother. 2012;13:2355–2367.
   PubMed Web of Science ®Google Scholar
• Mallolas J, Podzamczer D, Milinkovic A, et al. Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing regimens in real-life conditions. HIV Med. 2010;11:545–553.
   PubMed Web of Science ®Google Scholar
• Sevinsky H, Tao X, Wang R, et al. A randomized trial in healthy subjects to assess the bioequivalence of an atazanavir/cobicistat fixed-dose combination tablet versus administration as separate agents. Antivir Ther. 2015;20(5):493–500.
   PubMed Web of Science ®Google Scholar
• Elion R, Cohen C, Gathe J, et al. Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection. AIDS. 2011;25(15):1881–1886.
   PubMed Web of Science ®Google Scholar
• Gallant JE, Koenig E, Andrade-Villanueva JF, et al. Brief report: cobicistat compared with ritonavir as a pharmacoenhancer for atazanavir in combination with emtricitabine/tenofovir disoproxil fumarate: week 144 results. J Acquir Immune Defic Syndr. 2015;69:338–340.
   PubMed Web of Science ®Google Scholar
• Tashima K, Crofoot G, Tomaka FL, et al. Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial. AIDS Res Ther. 2014;11:39.
   PubMed Web of Science ®Google Scholar
• Marzolini C, Gibbons S, Khoo S, et al. Cobicistat versus ritonavir boosting and differences in the drug–drug interaction profiles with co-medications. Expert Opin Pharmacother. 2012;13:2355–2367.
   PubMed Web of Science ®Google Scholar
• Moyle GJ, Sabin CA, Cartledge J, et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS. 2006;20:2043–2050.
   PubMed Web of Science ®Google Scholar
• Martin A, Bloch M, Amin J, et al. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-lamivudine: a randomized, 96-week trial. Clin Infect Dis. 2009;49:1591–1601.
   PubMed Web of Science ®Google Scholar
• Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51–F58.
   PubMed Web of Science ®Google Scholar
• Duran S, Savès M, Spire B, et al. Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS. 2001;15:2441–2444.
   PubMed Web of Science ®Google Scholar
• John M, McKinnon EJ, James IR, et al. Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients. J Acquir Immun Defic Syndr. 2003;33:29–33.
   PubMed Web of Science ®Google Scholar
• Moyle GJ, Baldwin C, Langroudi B, et al. A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy. J Acquir Immun Defic Syndr. 2003;33:22–28.
   PubMed Web of Science ®Google Scholar
• Martínez E, Arranz JA, Podzamczer D, et al. A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression. J Acquir Immune Defic Syndr. 2009;51:290–297.
   PubMed Web of Science ®Google Scholar
• Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356:1723–1735.
   PubMed Web of Science ®Google Scholar
• Moyle GJ, Orkin C, Fisher M, et al. A randomized comparative trial of continued abacavir/lamivudine plus efavirenz or replacement with efavirenz/emtricitabine/tenofovir DF in hypercholesterolemic HIV-1 infected individuals. PLoS One. 2015;10:e0116297.
   PubMed Web of Science ®Google Scholar
• Smith KY, Patel P, Fine D, et al. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS. 2009;23:1547–1556.
   PubMed Web of Science ®Google Scholar
• Post FA, Moyle GJ, Stellbrink HJ, et al. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr. 2010;55:49–57.
   PubMed Web of Science ®Google Scholar
• Sax PE, Tierney C, Collier AC, et al. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis. 2011;204:1191–1201.
   PubMed Web of Science ®Google Scholar
• Negredo E, Domingo P, Pérez-Álvarez N, et al. Improvement in bone mineral density after switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: two-centre randomized pilot study (OsteoTDF study). J Antimicrob Chemother. 2014;69:3368–3371.
   PubMed Web of Science ®Google Scholar
• Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS. 2006;20:2165–2174.
   PubMed Web of Science ®Google Scholar
• Gutiérrez F, Masiá M. The role of HIV and antiretroviral therapy in bone disease. AIDS Rev. 2011;13:109–118.
   PubMed Web of Science ®Google Scholar
• McComsey GA, Kitch D, Daar ES, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: AIDS Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis. 2011;203:1791–1801.
   PubMed Web of Science ®Google Scholar
• Duvivier C, Kolta S, Assoumou L, et al. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS. 2009;23:817–824.
   PubMed Web of Science ®Google Scholar
• Haskelberg H, Hoy JF, Amin J, et al. Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofoviremtricitabine or abacavir-lamivudine. PLoS One. 2012;7:e38377.
   PubMed Web of Science ®Google Scholar
• Rasmussen TA, Jensen D, Tolstrup M, et al. Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial. PLoS One. 2012;7:e32445.
   PubMed Web of Science ®Google Scholar
• Brown TT, McComsey GA, King MS, et al. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr. 2009;51:554–561.
   PubMed Web of Science ®Google Scholar
• van Vonderen MGA, Lips P, van Agtmael MA, et al. First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir. AIDS. 2009;23:1367–1376.
   PubMed Web of Science ®Google Scholar
• Stellbrink H-J, Orkin C, Arribas JR, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis. 2010;51:963–972.
   PubMed Web of Science ®Google Scholar
• Hansen AB, Obel N, Nielsen H, et al. Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial. HIV Med. 2011;12:157–165.
   PubMed Web of Science ®Google Scholar
• Pozniak A, Arribas J, Gathe J, et al. Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: 48 week results from a single-arm, multi-center, open-label, Phase 3 study. J Acquir Immune Defic Syndr. 2016;71:530–537.
   Web of Science ®Google Scholar
• Ibrahim F, Hamzah L, Jones R, et al. Baseline kidney function as predictor of mortality and kidney disease progression in HIV-positive patients. Am J Kidney Dis. 2012;60:539–547.
   PubMed Web of Science ®Google Scholar
• Sax P, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 2015;385:2606–2615.
   PubMed Web of Science ®Google Scholar
• Behrens G, Maserati R, Rieger A, et al. Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles. Antivir Ther. 2012;17:1011–1020.
   PubMed Web of Science ®Google Scholar
• van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN study. Lancet. 2004;363:1253–1263.
   PubMed Web of Science ®Google Scholar
• Behrens G, Rijnders B, Nelson M, et al. Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naïve HIV-1-infected patients with HIV-1 RNA ≤100,000 copies/mL: week 96 pooled ECHO/THRIVE subanalysis. AIDS Patient Care STDS. 2014;28:168–175.
   PubMed Web of Science ®Google Scholar
• Mollan KR, Smurzynski M, Eron JJ, et al. Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. Ann Intern Med. 2014;161:1–10.
   PubMed Web of Science ®Google Scholar
• Smith C, Ryom L, Monforte A, et al. Lack of association between use of efavirenz and death from suicide: evidence from the D:A:D study. J Int AIDS Soc. 2014;17:19512.
   PubMed Web of Science ®Google Scholar
• Napoli AA, Wood JJ, Coumbis JJ, et al. No evident association between efavirenz use and suicidality was identified from a disproportionality analysis using the FAERS database. J Int AIDS Soc. 2014;17:19214.
   PubMed Web of Science ®Google Scholar
• Mills AM, Cohen C, Dejesus E, et al. Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens. HIV Clin Trials. 2013;14:216–223.
   PubMed Web of Science ®Google Scholar
• Nelson M, Winston A, Waters L, et al. Multicentre open-label study of switching from atripla to eviplera for possible efavirenz associated CNS toxicity. 53rd ICAAC; 2013 Sep 10–13; Denver, CO. Abstract H-672b.
   Google Scholar
• Nguyen A, Calmy A, Delhumeau C, et al. A randomized crossover study to compare efavirenz and etravirine treatment. AIDS. 2011;25:57–63.
   PubMed Web of Science ®Google Scholar
• Waters L, Fisher M, Winston A, et al. A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine. AIDS. 2011;25:65–71.
   PubMed Web of Science ®Google Scholar
• Sinxadi PZ, McIlleron HM, Dave JA, et al. Plasma efavirenz concentrations are associated with lipid and glucose concentrations. Medicine (Baltimore). 2016;95:e2385.
   PubMed Web of Science ®Google Scholar
• Thamrongwonglert P, Chetchotisakd P, Anunnatsiri S, et al. Improvement of lipid profiles when switching from efavirenz to rilpivirine in HIV-infected patients with dyslipidemia. HIV Clin Trials. 2016;7:1–5.
   Google Scholar
• Fundarò C, Genovese O, Rendeli C, et al. Myelomeningocele in a child with intrauterine exposure to efavirenz. AIDS. 2002;16:299–300.
   PubMed Web of Science ®Google Scholar
• De Santis M, Carducci B, De Santis L, et al. Periconceptional exposure to efavirenz and neural tube defects. Arch Intern Med. 2002;162:355.
   PubMed Web of Science ®Google Scholar
• Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1- Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. [ cited 2016 Mar 30]. Available from: http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf.
   Google Scholar
• Dejesus E, Young B, Morales-Ramirez JO, et al. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients. J Acquir Immune Defic Syndr. 2009;51:163–174.
   PubMed Web of Science ®Google Scholar
• Bucher HC, Kofler A, Nüesch R, et al. Meta-analysis of randomized controlled trials of simplified versus continued protease inhibitor-based antiretroviral therapy in HIV-1-infected patients. AIDS. 2003;17:2451–2459.
   PubMed Web of Science ®Google Scholar
• Maggiolo F, Ripamonti D, Suter F. Switch strategies in patients on effective HAART. J Antimicrob Chemother. 2005;55:821–823.
   PubMed Web of Science ®Google Scholar
• Ena J, Leach A, Nguyen P. Switching from suppressive protease inhibitor-based regimens to nevirapine-based regimens: a meta-analysis of randomized controlled trials. HIV Med. 2008;9:747–756.
   PubMed Web of Science ®Google Scholar
• Martínez E, Arnaiz JA, Podzamczer D, et al. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med. 2003;349:1036–1046.
   PubMed Web of Science ®Google Scholar
• Fisac C, Fumero E, Crespo M, et al. Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine. AIDS. 2005;19:917–925.
   PubMed Web of Science ®Google Scholar
• Gil P, De Górgolas M, Estrada V, et al. Long-term efficacy and safety of protease inhibitor switching to nevirapine in HIV-infected patients with undetectable virus load. Clin Infect Dis. 2004;39:1024–1029.
   PubMed Web of Science ®Google Scholar
• Palella FJ Jr., Fisher M, Tebas P, et al. Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants. AIDS. 2014;28:335–344.
   PubMed Web of Science ®Google Scholar
• Martínez E, Larrousse M, Llibre JM, et al. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS. 2010;24:1697–1707.
   PubMed Web of Science ®Google Scholar
• Eron JJ, Young B, Cooper DA, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet. 2010;375:396–407.
   PubMed Web of Science ®Google Scholar
• Shafran SD, Mashinter LD, Roberts SE. The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations. HIV Med. 2005;6:421–425.
   PubMed Web of Science ®Google Scholar
• The DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356:1723–1735.
   PubMed Web of Science ®Google Scholar
• Riddler SA, Li X, Otvos J, et al. Antiretroviral therapy is associated with an atherogenic lipoprotein phenotype among HIV-1-infected men in the Multicenter AIDS Cohort Study. J Acquir Immune Defi c Syndr. 2008;48:281–288.
   PubMed Web of Science ®Google Scholar
• Arribas JR, Pialoux G, Gathe J, et al. Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial. Lancet Infect Dis. 2014;14:581–589.
   PubMed Web of Science ®Google Scholar
• Molina JM, Clotet B, van Lunzen J, et al. Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. Lancet HIV. 2015;2:e127–e136.
   PubMed Web of Science ®Google Scholar
• van Lunzen J, Maggiolo F, Arribas JR, et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis. 2012;12:111–118.
   PubMed Web of Science ®Google Scholar
• Min S, Sloan L, DeJesus E, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults. AIDS. 2011;25:1737–1745.
   PubMed Web of Science ®Google Scholar
• Daar ES, Tierney C, Fischl MA, et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med. 2011;154:445–456.
   PubMed Web of Science ®Google Scholar
• Cardiovascular risk in HIV patients switching from a boosted protease inhibitor (PI) to dolutegravir (DTG). (NEAT 22/SSAT 060 study). [ cited 2016 Mar 30]. Available from: https://clinicaltrials.gov/.
   Google Scholar
• Nguyen A, Calmy A, Delhumeau C, et al. A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study). AIDS. 2011;25:1481–1487.
   PubMed Web of Science ®Google Scholar
• Bloch M, Tong WW, Hoy J, et al. Switch from tenofovir to raltegravir increases low bone mineral density and decreases markers of bone turnover over 48 weeks. HIV Med. 2014;15:373–380.
   PubMed Web of Science ®Google Scholar
• Regimen switch to dolutegravir + rilpivirine from current antiretroviral regimen in human immunodeficiency virus type 1 infected and virologically suppressed adults (SWORD-1). (NCT02429791). [ cited 2016 May 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT02429791?term=sword-1&rank=1.
   Google Scholar
• Trottier B, Lake J, Logue K, et al. Switching to abacavir/dolutegravir/lamivudine fixed dose combination (ABC/DTG/3TC FDC) from a PI, INI or NNRTI based regiment maintains HIV suppression. 55th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2015 Sep 17–21; San Diego, CA.
   Google Scholar
• Lake J, Currier J, Koteff J, et al. Cardiovascular biomarkers after switching to ABC/DTG/3TC: the STRIIVING study. 23 Conference on Retroviruses and Opportunistic Infections; 2016 Feb 22–25; Boston, MA
   Google Scholar
• Arribas JR, Clumeck N, Nelson M, et al. The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load < 50 HIV-1 RNA copies/mL at baseline. HIV Med. 2012;13:398–405.
   PubMed Web of Science ®Google Scholar
• Arribas JR, Delgado R, Arranz A, et al. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis. J Acquir Immune Defic Syndr. 2009;51:147–152.
   PubMed Web of Science ®Google Scholar
• Paton NI, Stohr W, Arenas-Pinto A, et al. Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial. Lancet HIV. 2015;2:e417–e426.
   PubMed Web of Science ®Google Scholar
• Antinori A, Arribas J, Fehr J, et al. The PROTEA trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV-1 RNA below 50 copies/mL. J Int AIDS Soc. 2014;17(4 Suppl 3):19525.
   PubMed Web of Science ®Google Scholar
• Crosby P. Reflections on quality. New York (NY): McGraw-Hill; 1995.
   Google Scholar